menu
    • menu

    Company profile for Stemline Therapeutics

    NEW Drugs in Dev.: 12
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics. ELZONRIS® (tagraxofusp),...
    Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics. ELZONRIS® (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Stemline TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    750 Lexington Avenue, 11th Floor New York, NY 10022
    Telephone
    Telephone
    646-502-2310
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://stemline.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Menarini to Present Elacestrant Data on ER+ HER2- mBC in 2025
    Menarini to Present Elacestrant Data on ER+ HER2- mBC in 2025

    09 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/menarini-group-presents-elacestrant-orserdu-phase-2-combination-data-in-patients-with-er-her2--metastatic-breast-cancer-mbc-at-the-2025-san-antonio-breast-cancer-symposium-302635656.html

    PR NEWSWIRE
    09 Dec 2025
    Share Share
    Menarini Group Unveils Elzonris Data at ASH Annual Meeting
    Menarini Group Unveils Elzonris Data at ASH Annual Meeting

    24 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/menarini-group-announces-new-data-on-elzonris-tagraxofusp-erzs-to-be-presented-at-the-67th-american-society-of-hematology-annual-meeting-and-exposition-302624638.html

    PR NEWSWIRE
    24 Nov 2025
    Share Share
    Tempus & Stemline Partner To Implement AI-Enabled Care For Cancer
    Tempus & Stemline Partner To Implement AI-Enabled Care For Cancer

    21 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/21/3030444/21662/en/Tempus-and-Stemline-Therapeutics-Inc-A-Subsidiary-of-the-Menarini-Group-Announce-Collaboration-to-Implement-Tempus-Next-an-AI-Enabled-Care-Pathway-Intelligence-Platform-to-Support-.html

    GLOBENEWSWIRE
    21 Feb 2025
    Share Share
    Menarini Group & Medsir Present Ph 3 ADELA Study for Breast Cancer
    Menarini Group & Medsir Present Ph 3 ADELA Study for Breast Cancer

    11 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241211008868/en

    BUSINESSWIRE
    11 Dec 2024
    Share Share
    Insilico nabs $500M+ biobucks deal for preclinical cancer asset
    Insilico nabs $500M+ biobucks deal for preclinical cancer asset

    04 Jan 2024

    // Gabrielle Masson FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/menarini-groups-stemline-inks-500m-biobucks-deal-insilicos-breast-cancer-candidate

    Gabrielle Masson FIERCE BIOTECH
    04 Jan 2024
    Share Share
    Stemline Therapeutics' Orserdu (elacestrant) Receives Approval in Europe
    Stemline Therapeutics' Orserdu (elacestrant) Receives Approval in Europe

    09 Oct 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/orserdu-epar-medicine-overview_en.pdf

    EMA
    09 Oct 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search